179
Participants
Start Date
November 12, 2012
Primary Completion Date
September 16, 2016
Study Completion Date
September 16, 2016
BYL719 as film-coated (FC) whole tablets
Oral alpha-specific PI3K inhibitor
BYL719 as dispersible tablets (DT)
New formulation of the oral alpha-specific PI3K inhibitor
cetuximab
Recombinant chimeric monoclonal antibody driven against EGFR
BYL719 drink suspension
Oral alpha-specific PI3K inhibitor
Novartis Investigative Site, Melbourne
Novartis Investigative Site, Maastricht
Novartis Investigative Site, Murdoch
Novartis Investigative Site, New York
Novartis Investigative Site, New York
Novartis Investigative Site, Taipei
Novartis Investigative Site, Philadelphia
Novartis Investigative Site, Charleston
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Jacksonville
Novartis Investigative Site, Orlando
Novartis Investigative Site, Kuei-Shan Chiang
Novartis Investigative Site, Nashville
Novartis Investigative Site, St Louis
Novartis Investigative Site, Lyon
Novartis Investigative Site, Tainan City
Novartis Investigative Site, Houston
Novartis Investigative Site, Aurora
Novartis Investigative Site, San Francisco
Novartis Investigative Site, Sacramento
Novartis Investigative Site, Singapore
Novartis Investigative Site, Boston
Novartis Investigative Site, Toronto
Novartis Investigative Site, Shatin, New Territories
Novartis Investigative Site, Nijmegen
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY